Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07560709 | Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma | no longer available | — | — | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04667234 | Expanded Access of Sotorasib | no longer available | — | — | AmgenINDUSTRY | 6 | Aug 20, 2026 | clinicaltrials |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma(AMPLIFY-EAP) |
| no longer available |
| — |
| — |
| Elicio TherapeuticsINDUSTRY |
| 0 |
| Jul 10, 2026 |
| clinicaltrials |
| NCT03874455 | Tazemetostat Expanded Access Program for Adults With Solid Tumors | no longer available | — | — | Epizyme, Inc.INDUSTRY | 0 | Jul 2, 2026 | clinicaltrials |
| NCT04225429 | Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | no longer available | — | — | Epizyme, Inc.INDUSTRY | 0 | Jul 2, 2026 | clinicaltrials |
| NCT06090331 | 89Zr-DFO-girentuximab Expanded Access Program (EAP) | no longer available | — | — | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06743100 | 18F-Floretyrosine Expanded Access Program | no longer available | — | — | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT05100134 | Managed Access Programs for LDK378, Ceritinib | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 1, 2026 | clinicaltrials |
| NCT04741789 | Managed Access Programs for INC280, Capmatinib | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT07399015 | Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC | no longer available | — | — | Endevica BioINDUSTRY | 0 | Feb 18, 2026 | clinicaltrials |
| NCT06439966 | Expanded Access to ABBV-787 | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06195514 | Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC) | no longer available | — | — | TakedaINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT00590915 | Erwinase Master Treatment Protocol(EMTP) | no longer available | — | — | Phoenix Children's HospitalOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT03756311 | Expanded Access to NanoPac | no longer available | — | — | NanOlogy, LLCINDUSTRY | 0 | Jan 23, 2026 | clinicaltrials |
| NCT06063746 | Compassionate Use of Vidutolimod | no longer available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Jan 8, 2026 | clinicaltrials |
| NCT06841874 | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC(Tale EAP) | no longer available | — | — | Nuvation Bio Inc.INDUSTRY | 0 | Dec 24, 2025 | clinicaltrials |
| NCT04489433 | Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 18, 2025 | clinicaltrials |
| NCT06590480 | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma(RPL-EAP-001) | no longer available | — | — | Replimune, Inc.INDUSTRY | 0 | Dec 18, 2025 | clinicaltrials |
| NCT05161598 | Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 16, 2025 | clinicaltrials |
| NCT05503550 | Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 16, 2025 | clinicaltrials |
| NCT05269771 | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 8 | Nov 5, 2025 | clinicaltrials |
| NCT07223606 | Fecal Microbiota Transplant for Neuroblastoma in a Single Patient | no longer available | — | — | ProgenaBiomeOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04087889 | Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer | no longer available | — | — | Hope Biosciences LLCINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04802447 | SurVaxM Expanded Access Protocol(EAP) | no longer available | — | — | Roswell Park Cancer InstituteOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT05918913 | Expanded Access Program for Revumenib | no longer available | — | — | Syndax PharmaceuticalsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04681248 | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | no longer available | — | — | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT04313075 | A Compassionate Use Study of Leronlimab in Breast Cancer | no longer available | — | — | CytoDyn, Inc.INDUSTRY | 0 | Jul 15, 2025 | clinicaltrials |
| NCT04452994 | Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 13, 2025 | clinicaltrials |
| NCT03593499 | Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401 | no longer available | — | — | BiogenINDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT03493165 | Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT04087876 | Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations | no longer available | — | — | Basilea PharmaceuticaINDUSTRY | 0 | Apr 6, 2025 | clinicaltrials |
| NCT03414489 | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | no longer available | — | — | RedHill Biopharma LimitedINDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT05683548 | Replicor Compassionate Access Program(RCAP) | no longer available | — | — | Replicor Inc.INDUSTRY | 5 | Feb 17, 2025 | clinicaltrials |
| NCT05238311 | Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | no longer available | — | — | PfizerINDUSTRY | 0 | Feb 4, 2025 | clinicaltrials |
| NCT05215405 | Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL | no longer available | — | — | Kathleen LudwigOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03649438 | 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | no longer available | — | — | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04507919 | Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT04544202 | Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT05518838 | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered | no longer available | — | — | Oblato, Inc.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04714086 | Expanded Access Program for Avapritinib | no longer available | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Oct 24, 2024 | clinicaltrials |
| NCT04052854 | A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies | no longer available | — | — | BeiGeneINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05936216 | TVI-Brain-1 in Expanded Access Patient | no longer available | — | — | TVAX BiomedicalINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03420430 | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | no longer available | — | — | Genelux CorporationINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05462639 | Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma(MAGNETISMM17) | no longer available | — | — | PfizerINDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT05551013 | Treatment of Recurrent GBM With APG-157 Via Expanded Access | no longer available | — | — | Aveta Biomics, Inc.INDUSTRY | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06439849 | Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma(TRIANGLE) | no longer available | — | — | Petrov, AndreyOTHER | 0 | Jul 16, 2024 | clinicaltrials |
| NCT05219266 | Managed Access Programs for PKC412, Midostaurin | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 28, 2024 | clinicaltrials |
| NCT03592576 | Expanded Access to Navitoclax | no longer available | — | — | AbbVieINDUSTRY | 0 | May 6, 2024 | clinicaltrials |
| NCT04321694 | Expanded Access for KHK2455 | no longer available | — | — | Kyowa Kirin, Inc.INDUSTRY | 0 | Apr 25, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials